ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Cipla Ltd.

Company Background

Cipla is a major Indian generic drugmaker, competing for second place in the industry in India in terms of the size of its business. It has been doing business in 170 countries and has over 30 production bases. It is a long-established company compared with other Indian leading generic drugmakers. The predecessor of Cipla was founded by K. A. Hamied in 1935, long before India's independence in 1947. It is said that Mahatma Gandhi visited Cipla and asked Hamied to supply medicines that were desperately needed in India at the time. During World War II, Hamied crisscrossed the country to supply medicines that were in short supply due to stagnant imports.

As a trailblazer in India's pharmaceutical industry, Cipla has been busily expanding its business in Africa and other emerging economies. In particular, it is well-known for its low-cost HIV drug. In 2013, it turned a South African company it did business with into a wholly owned subsidiary.

K. A. Hamied's son Yusuf, who earned a doctorate in organic chemistry from the University of Cambridge, took over the company in 1972 and has been serving as the chairman. The founding family owns nearly 40% of the shares in the company.

Business Summary

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2022 INRUSD
Gross Profit71,938.80M965.49M
Operating income36,176.80M485.53M
Income before tax34,932.70M468.83M
Net income25,167.50M337.77M
Diluted EPS31.160.41
Dividends Per Share50.06
Total Assets271,011.20M3,576.52M
Total liabilities59,769.10M788.77M
Total equity208,416.90M2,750.47M
Operating cash flow32,972.40M442.52M
Currency in INRCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 150,110.30M 161,887.40M 168,571.40M 190,622.50M 217,257.90M
Gross Profit 52,774.30M 51,888.70M 53,964.60M 60,761M 71,938.80M
Operating income 17,775.30M 18,901.50M 19,122.50M 32,051.60M 36,176.80M
Income before tax 16,694.60M 20,791.40M 21,781.80M 32,900.60M 34,932.70M
Net income 14,105.30M 15,277M 15,465.20M 24,048.70M 25,167.50M
EBITDA 27,273.40M 29,858.10M 30,095.60M 42,057.30M 46,055.10M
Diluted EPS 17.50 18.93 19.16 29.78 31.16
Dividends Per Share 3 3 3 5 5
Total Assets 228,605.50M 239,633.20M 236,625.60M 251,518.90M 271,011.20M
Total liabilities 82,633.90M 86,090.80M 75,963.70M 65,587.20M 59,769.10M
Total equity 142,291.90M 150,122.80M 157,630M 183,265.30M 208,416.90M
Operating cash flow 13,781.60M 16,047.80M 29,550.80M 36,966.50M 32,972.40M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 2,328.51M 2,314.57M 2,377.39M 2,567.82M 2,915.83M
Gross Profit 818.63M 741.87M 761.07M 818.49M 965.49M
Operating income 275.73M 270.24M 269.68M 431.75M 485.53M
Income before tax 258.96M 297.26M 307.19M 443.19M 468.83M
Net income 218.80M 218.42M 218.10M 323.95M 337.77M
EBITDA 423.06M 426.89M 424.44M 566.54M 618.10M
Diluted EPS 0.27 0.27 0.27 0.40 0.41
Dividends Per Share 0.04 0.04 0.04 0.06 0.06
Total Assets 3,505.05M 3,459.15M 3,127.84M 3,440.10M 3,576.52M
Total liabilities 1,266.96M 1,242.73M 1,004.13M 897.05M 788.77M
Total equity 2,181.66M 2,167.05M 2,083.64M 2,506.57M 2,750.47M
Operating cash flow 213.78M 229.44M 416.76M 497.96M 442.52M

Valuation Measures

Mar 2022
Operating margin16.65%
Profit margin11.58%

Key executives

  • Global CEO, MD & Executive Director: Umang Vohra
  • Co-President & Global Chief People Officer: Raju Mistry
  • Co-President & Global Chief Scientific Officer: Pradeep Bhadauria
  • Global Chief Financial Officer: Ashish Adukia
  • Global Chief Medical Officer: Jaideep A. Gogtay


  • AHMED SOPHIE (5.6%)
  • SBI Funds Management Pvt Ltd. (4.6%)
  • HDFC Asset Management Co. Ltd. (Invt Mgmt) (2.3%)
  • Life Insurance Corporation of India (Investment Portfolio) (2.2%)
  • Norges Bank Investment Management (2.2%)
  • The Vanguard Group, Inc. (2.0%)
  • BlackRock Fund Advisors (1.7%)

Contact Details

  • Website:
  • Address: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Mumbai, 400013, India
  • Phone: +91.22.24826000

Related Companies

  • CIpla Ilac TIcaret AS
  • Madison Pharmaceuticals, Inc.
  • Cipla Gulf FZ LLC
  • Cipla Technologies LLC
  • Cipla BioTec South Africa (Pty) Ltd.
  • Cipla Philippines, Inc.
  • Cipla Middle East Pharmaceuticals FZ LLC
  • Medica Pharmaceutical Industries Co. Ltd.
  • Breathe Free Lanka Pvt Ltd.
  • Cipla Medpro Botswana Pty Ltd.
  • Cipla Medpro Distribution Centre Pty Ltd.
  • Cipla Life Sciences Pty Ltd.
  • Cipla Dibcare Pty Ltd.
  • Cape to Cairo Exports Pty Ltd.
  • Cipla Medpro Holdings Pty Ltd.
  • Cipla Malaysia Sdn. Bhd.
  • Cipla Kenya Ltd.
  • Cipla Australia Pty Ltd.
  • Cipla (Mauritius) Ltd.
  • Sitec Labs Ltd.
  • Wanbury Ltd. /4 Brands/
  • AJM Pharma (Pvt) Ltd.
  • Goldencross Pharma Pvt Ltd.
  • Cipla Europe NV
  • Inyanga Trading 386 (Pty) Ltd.
  • Cipla USA, Inc.
  • Meditab Holdings Ltd.
  • Quality Chemicals Ltd.
  • Jay Precision Pharmaceuticals Pvt Ltd.
  • Medispray Laboratories Pvt Ltd.


  • Dr. Reddy's Laboratories Ltd.
  • CMG Pharmaceutical Co., Ltd.
  • Adcock Ingram Holdings Limited
  • Knight Therapeutics, Inc.
  • Amneal Pharmaceuticals, Inc. Class A
  • Amphastar Pharmaceuticals, Inc.
  • Spero Therapeutics, Inc.
  • Innoviva, Inc.
  • Iterum Therapeutics plc
  • Crinetics Pharmaceuticals Inc
  • Bora Pharmaceuticals Co Ltd
Last Updated on 17 Mar, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more